Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 1/20 | 0.53 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | CFTR | P13569 | 1/20 | 0.44 |
| ▸ | BRD4 | O60885 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.43 |
| ▸ | NR4A2 | P43354 | 3/20 | 0.43 |
| ▸ | PTPRC | P08575 | 1/20 | 0.43 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.42 |
| ▸ | ERN1 | O75460 | 2/20 | 0.42 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.42 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL870174 | 0.90 | BRD4 (0.47) | PIM1PIM3ALDH1A1POLBRAB9A | |
| SCHEMBL70429 | 0.85 | LMNA (0.59) | ALDH1A1POLBLMNATSHRHSD17B10 | |
| SCHEMBL1935692 | 0.82 | PIM1 (0.39) | PIM1PIM3ALDH1A1POLBRAB9A | |
| SCHEMBL121356 | 0.82 | LMNA (0.57) | PIM1PIM3ALDH1A1POLBRAB9A | |
| SCHEMBL30635255 | 0.82 | LMNA (0.57) | PIM1PIM3ALDH1A1POLBRAB9A | |
| SCHEMBL31184600 | 0.81 | ALDH1A1 (0.59) | PIM1PIM3ALDH1A1POLBRAB9A | |
| SCHEMBL29216778 | 0.81 | ALDH1A1 (0.49) | PIM1PIM3ALDH1A1POLBRAB9A | |
| SCHEMBL16566856 | 0.81 | ALDH1A1 (0.59) | PIM1PIM3ALDH1A1POLBRAB9A | |
| SCHEMBL7195201 | 0.81 | KDM4E (0.58) | PIM1PIM3ALDH1A1POLBRAB9A | |
| SCHEMBL26617428 | 0.81 | CA1 (0.50) | PIM1PIM3ALDH1A1POLBRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1701934-B1 | DISUBSTITUTED CHALCONE OXIMES HAVING RAR(Gamma)-RETINOID RECEPTOR ANTAGONIST ACTIVITY | ALLERGAN INC (US) | 2009-02-25 | — | — | EP | disclosed |
| US-7476673-B2 | Disubstituted chalcone oximes as selective agonists of RARγ retinoid receptors | ALLERGAN, INC. (US) | 2009-01-13 | — | — | US | disclosed |
| US-7432388-B2 | Disubstituted chalcone oximes having RARγ retinoid receptor antagonist activity | ALLERGAN, INC. (US) | 2008-10-07 | — | — | US | disclosed |
| US-20080097119-A1 | Disubstituted chalcone oximes having RARgamma retinoid receptor antagonist activity | TSANG KWOK Y | 2008-04-24 | — | — | US | disclosed |
| US-7253319-B2 | Disubstituted chalcone oximes having RARγ retinoid receptor antagonist activity | ALLERGAN, INC. (US) | 2007-08-07 | — | — | US | disclosed |
| EP-1704139-A1 | DISUBSTITUTED CHALCONE OXIMES AS SELECTIVE AGONISTS OF RAR y RETINOID RECEPTORS | Allergan, Inc. (US) | 2006-09-27 | — | — | EP | disclosed |
| EP-1701934-A2 | DISUBSTITUTED CHALCONE OXIMES HAVING RAR(Gamma)-RETINOID RECEPTOR ANTAGONIST ACTIVITY | Allergan, Inc. (US) | 2006-09-20 | — | — | EP | disclosed |
| US-20050165095-A1 | Disubstituted chalcone oximes having RARy retinoid receptor antagonist activity | ALLERGAN, INC. | 2005-07-28 | — | — | US | disclosed |
| WO-2005066116-A1 | DISUBSTITUTED CHALCONE OXIMES AS SELECTIVE AGONISTS OF RARϜ RETINOID RECEPTORS | ALLERGAN, INC. (US) | 2005-07-21 | — | — | WO | disclosed |
| WO-2005066115-A2 | DISUBSTITUTED CHALCONE OXIMES HAVING RARϜ RETINOID RECEPTOR ANTAGONIST ACTIVITY | ALLERGAN, INC. (US) | 2005-07-21 | — | — | WO | disclosed |
| US-20050148590-A1 | Disubstituted chalcone oximes as selective agonists of RAR retinoid receptors | ALLERGAN, INC. | 2005-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080097119-A1 | Disubstituted chalcone oximes having RARgamma retinoid receptor antagonist activity | RARG, RARB, RARA | PIM1 4227/4885PIM3 4123/4885ALDH1A1 421/4885 |
| US-20050165095-A1 | Disubstituted chalcone oximes having RARy retinoid receptor antagonist activity | RARB, RARG, RARA | PIM1 4544/4885PIM3 4403/4885ALDH1A1 398/4885 |
| US-20050148590-A1 | Disubstituted chalcone oximes as selective agonists of RAR retinoid receptors | RARG, RXRG, RARB | PIM1 4082/4885PIM3 4262/4885ALDH1A1 1103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.